What's in Beijing Minhai Biotechnology Co., Ltd's pipeline?

Beijing Minhai Biotechnology Co., Ltd has 11 drugs in our index: 0 marketed, 0 filed, 11 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Beijing Minhai Biotechnology Co., Ltd's portfolio?

Top competitors by shared drug class: Pfizer, GlaxoSmithKline, Merck Sharp & Dohme LLC, CanSino Biologics Inc., Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/beijing-minhai-biotechnology-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Beijing Minhai Biotechnology Co., Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beijing Minhai Biotechnology Co., Ltd pipeline: 0 marketed, 0 filed, 11 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 11 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
MPV-ACYW135 Vaccine Group	MPV-ACYW135 Vaccine Group	phase 3	Meningococcal conjugate vaccine		Immunology
wIPV	wIPV	phase 3	SARS-CoV-2 main protease inhibitor	SARS-CoV-2 main protease	Infectious Diseases
MPV-A Vaccine Group	MPV-A Vaccine Group	phase 3	vaccine		Immunology
MCV-AC Vaccine Group	MCV-AC Vaccine Group	phase 3	Conjugate vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsules	Immunology / Infectious Disease
MCV-ACYW135 Vaccine Group	MCV-ACYW135 Vaccine Group	phase 3	Meningococcal conjugate vaccine		Immunology
wIPV+bOPV	wIPV+bOPV	phase 3	Vaccine	SARS-CoV-2	Infectious Disease
Hib Vaccine Group	Hib Vaccine Group	phase 3	vaccine	Haemophilus influenzae type b polysaccharide capsule	Immunology
Minhai-HIB	Minhai-HIB	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule	Immunology / Infectious Disease
pneumococcal disease prevention	pneumococcal disease prevention	phase 3
sIPV+bOPV	sIPV+bOPV	phase 3			Infectious Diseases
Act-HIB®	Act-HIB®	phase 3	Conjugate vaccine	Haemophilus influenzae type b capsular polysaccharide (PRP)	Immunology / Infectious Disease

Therapeutic area mix

Immunology · 4
Immunology / Infectious Disease · 3
Infectious Diseases · 2
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
CanSino Biologics Inc. · 4 shared drug classes
Novartis · 3 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 3 shared drug classes
International Vaccine Institute · 3 shared drug classes
Sanofi · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Beijing Minhai Biotechnology Co., Ltd:

Cite this brief

Drug Landscape (2026). Beijing Minhai Biotechnology Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-minhai-biotechnology-co-ltd. Accessed 2026-05-16.